Guardant Health, Inc. $GH Shares Acquired by Edgestream Partners L.P.

Edgestream Partners L.P. increased its position in shares of Guardant Health, Inc. (NASDAQ:GH) by 321.6% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 32,257 shares of the company’s stock after purchasing an additional 24,606 shares during the period. Edgestream Partners L.P.’s holdings in Guardant Health were worth $2,980,000 as of its most recent SEC filing.

A number of other hedge funds have also recently added to or reduced their stakes in GH. V Square Quantitative Management LLC acquired a new position in Guardant Health during the 4th quarter worth approximately $27,000. Thurston Springer Miller Herd & Titak Inc. purchased a new position in shares of Guardant Health during the 4th quarter worth approximately $31,000. Elyxium Wealth LLC acquired a new stake in shares of Guardant Health in the 4th quarter valued at approximately $35,000. Parallel Advisors LLC lifted its holdings in shares of Guardant Health by 164.7% in the 4th quarter. Parallel Advisors LLC now owns 352 shares of the company’s stock valued at $36,000 after buying an additional 219 shares during the period. Finally, Ascentis Independent Advisors acquired a new stake in shares of Guardant Health in the 1st quarter valued at approximately $38,000. Institutional investors and hedge funds own 92.60% of the company’s stock.

Insider Buying and Selling

In other news, Director Musa Tariq sold 1,951 shares of the firm’s stock in a transaction on Monday, June 22nd. The stock was sold at an average price of $131.16, for a total value of $255,893.16. Following the completion of the transaction, the director owned 11,048 shares in the company, valued at $1,449,055.68. This trade represents a 15.01% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Amirali Talasaz sold 143,028 shares of Guardant Health stock in a transaction on Monday, June 29th. The stock was sold at an average price of $151.54, for a total value of $21,674,463.12. Following the transaction, the chief executive officer directly owned 1,881,336 shares of the company’s stock, valued at $285,097,657.44. This trade represents a 7.07% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 708,565 shares of company stock valued at $90,556,597 in the last three months. 5.60% of the stock is owned by insiders.

Analysts Set New Price Targets

GH has been the topic of a number of recent analyst reports. JPMorgan Chase & Co. upped their price objective on Guardant Health from $185.00 to $195.00 and gave the stock an “overweight” rating in a report on Friday. Sanford C. Bernstein boosted their target price on shares of Guardant Health from $175.00 to $200.00 and gave the stock an “outperform” rating in a research report on Thursday, July 2nd. Royal Bank Of Canada upped their price target on shares of Guardant Health from $185.00 to $200.00 and gave the stock an “outperform” rating in a research note on Friday. BTIG Research increased their price target on shares of Guardant Health from $190.00 to $195.00 and gave the company a “buy” rating in a report on Friday. Finally, UBS Group set a $150.00 price objective on shares of Guardant Health in a research note on Wednesday, June 24th. One research analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Guardant Health currently has a consensus rating of “Moderate Buy” and an average target price of $179.82.

Guardant Health Price Performance

NASDAQ GH opened at $161.99 on Friday. The business has a 50 day moving average price of $143.44 and a 200 day moving average price of $113.38. The company has a market capitalization of $21.48 billion, a P/E ratio of -46.42 and a beta of 1.59. Guardant Health, Inc. has a 1-year low of $40.35 and a 1-year high of $176.58.

Key Stories Impacting Guardant Health

Here are the key news stories impacting Guardant Health this week:

• Positive Sentiment: Revenue and testing growth exceeded expectations. Second-quarter revenue rose 44% year over year to $335.0 million, above the $314.2 million analyst estimate. Oncology revenue increased 38% to $219.1 million, while oncology test volume climbed 63% to approximately 104,000. Guardant Health Reports Second Quarter 2026 Financial Results and Increases 2026 Revenue Guidance
• Positive Sentiment: Guardant raised its 2026 revenue guidance to $1.3 billion-$1.4 billion, compared with consensus around $1.3 billion. The outlook increase signals continued demand for the company’s cancer-screening and precision-oncology tests. Guardant Health hits 52-week high after guidance hike
• Positive Sentiment: JPMorgan raised its price target from $185 to $195 and maintained an “overweight” rating, reinforcing bullish analyst sentiment and suggesting additional potential upside. JPMorgan raises Guardant Health price target
• Neutral Sentiment: Guardant reported a second-quarter adjusted loss of $0.42 per share, compared with a $0.44 loss a year earlier. Reports differed on the consensus comparison, with one estimate showing a modest miss and another indicating a substantial beat. Guardant Health Q2 earnings report
• Negative Sentiment: Profitability remains a concern. Guardant continues to generate quarterly losses, and investor commentary is weighing whether rapidly rising revenue can offset ongoing spending and losses. Does Guardant’s Surging Revenue and Deeper Losses Reframe the Growth Thesis for GH?

About Guardant Health

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.